RK

Rajesh Kumar

Active Director Director DIN 08289625
DIN 08289625 First appointment Nov 2018 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2018
Shareholding value •••• Premium profile

About Rajesh Kumar

Data last updated:

Rajesh Kumar is a Director at Estocon Pharmaceuticals Private Limited (since 2018). The company operates in Healthcare. Estocon Pharmaceuticals Private Limited reported revenue of ₹11.6 Lakh (FY 2024).

DIN 08289625
Primary Designation Director
Industry Healthcare
First Appointment 28 Nov 2018
Oldest Company Age 7 yrs
Largest company Estocon Pharmaceuticals Private Limited · ₹11.6 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director28 Nov 20182018₹11.6 Lakh (FY 2024)Active

Board colleagues of Rajesh Kumar

Directorship timeline

Open interactive timeline →
Estocon Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Rajesh Kumar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rajesh Kumar

Rajesh Kumar currently holds 1 directorship: Estocon Pharmaceuticals Private Limited (Director, since 28 Nov 2018, revenue ₹11.6 Lakh (FY 2024)).

Rajesh Kumar was first appointed on 28 Nov 2018 as Director at Estocon Pharmaceuticals Private Limited.

The current boards of Rajesh Kumar's companies include Rakesh (Estocon Pharmaceuticals Private Limited), Ram Nayan (Estocon Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available